These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 20452456)

  • 1. Intravitreal therapy for neovascular age-related macular degeneration and inter-individual variations in vitreous pharmacokinetics.
    Laude A; Tan LE; Wilson CG; Lascaratos G; Elashry M; Aslam T; Patton N; Dhillon B
    Prog Retin Eye Res; 2010 Nov; 29(6):466-75. PubMed ID: 20452456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.
    Papadopoulou DN; Mendrinos E; Mangioris G; Donati G; Pournaras CJ
    Ophthalmology; 2009 Sep; 116(9):1755-61. PubMed ID: 19560206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guidance for the treatment of neovascular age-related macular degeneration.
    Schmidt-Erfurth UM; Richard G; Augustin A; Aylward WG; Bandello F; Corcòstegui B; Cunha-Vaz J; Gaudric A; Leys A; Schlingemann RO;
    Acta Ophthalmol Scand; 2007 Aug; 85(5):486-94. PubMed ID: 17655610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.
    Boyer DS; Heier JS; Brown DM; Francom SF; Ianchulev T; Rubio RG
    Ophthalmology; 2009 Sep; 116(9):1731-9. PubMed ID: 19643495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current treatment options for retinal angiomatous proliferans (RAP).
    Gupta B; Jyothi S; Sivaprasad S
    Br J Ophthalmol; 2010 Jun; 94(6):672-7. PubMed ID: 19897475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New therapies for neovascular age-related macular degeneration: critical appraisal of the current evidence.
    Virgili G; Do DV; Bressler NM; Menchini U
    Acta Ophthalmol Scand; 2007 Feb; 85(1):6-20. PubMed ID: 17244204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
    Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
    Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-VEGF agents for age-related macular degeneration.
    Ozkiris A
    Expert Opin Ther Pat; 2010 Jan; 20(1):103-18. PubMed ID: 20021287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging therapies for neovascular age-related macular degeneration: state of the art.
    Donati G
    Ophthalmologica; 2007; 221(6):366-77. PubMed ID: 17947822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
    Brown MM; Brown GC; Brown HC; Peet J
    Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Guidance for the treatment of neovascular age-related macular degeneration (AMD)].
    Karska-Basta I; Kubicka-Trzaska A; Oleksy P; Romanowska-Dixon B
    Przegl Lek; 2009; 66(11):972-5. PubMed ID: 20297641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2.
    Abraham P; Yue H; Wilson L
    Am J Ophthalmol; 2010 Sep; 150(3):315-324.e1. PubMed ID: 20598667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting.
    Cohen SY; Dubois L; Tadayoni R; Fajnkuchen F; Nghiem-Buffet S; Delahaye-Mazza C; Guiberteau B; Quentel G
    Am J Ophthalmol; 2009 Sep; 148(3):409-13. PubMed ID: 19477713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials.
    Suñer IJ; Kokame GT; Yu E; Ward J; Dolan C; Bressler NM
    Invest Ophthalmol Vis Sci; 2009 Aug; 50(8):3629-35. PubMed ID: 19255158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
    Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M
    Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration.
    Theodossiadis PG; Liarakos VS; Sfikakis PP; Vergados IA; Theodossiadis GP
    Am J Ophthalmol; 2009 May; 147(5):825-30, 830.e1. PubMed ID: 19211094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration.
    Rosenfeld PJ; Heier JS; Hantsbarger G; Shams N
    Ophthalmology; 2006 Apr; 113(4):623.e1. PubMed ID: 16581423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of neovascular age-related macular degeneration: past, present and future directions.
    Smith BT; Joseph DP; Grand MG
    Curr Opin Ophthalmol; 2007 May; 18(3):240-4. PubMed ID: 17435433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphological and functional analysis of the loading regimen with intravitreal ranibizumab in neovascular age-related macular degeneration.
    Bolz M; Simader C; Ritter M; Ahlers C; Benesch T; Prünte C; Schmidt-Erfurth U
    Br J Ophthalmol; 2010 Feb; 94(2):185-9. PubMed ID: 19692384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.